Hospira announces new executive appointment
LAKE FOREST, Ill. — Generic drug maker Hospira has appointed Matt Stober as its SVP operations, the company said.
Stober, who began working for Hospira in 2011 as corporate VP U.S. pharmacy operations, will have expanded leadership over all the company’s drug manufacturing, as well as manufacturing science and technology, engineering, competitive strategy, health and safety, supply chain and procurement. Stober succeeds John Elliot, who has led operations since April 2012 and will provide continuity of support until he retires at the end of the year.
"Matt brings the perfect blend of vision and experience to our operations organization, backed by a proven track record of success at Hospira," CEO F. Michael Ball said. "In his expanded role, we’re confident Matt will continue to successfully advance our dual commitment to remediate and modernize our processes and operations while delivering patient-critical products and ultimately establish our manufacturing operations as a strategic, competitive advantage."
Diplomat Specialty Pharmacy supports employee health and wellness with new programs
FLINT, Mich. — Diplomat Specialty Pharmacy has several new programs in the works to promote health and wellness among its employees, the company said.
Diplomat announced a new fitness center at its headquarters that will include stationary bikes, strength-training machines, ellipticals, medicine balls, an exercise video center and a Wii system.
In addition, the Flint, Mich.-based company is taking part in the Greater Flint Health Coalition’s Six Weeks to Wellness competition, in which businesses compete to encourage local employees to reach wellness goals. The company will also take part in an upcoming 5K race and participate in National Walk at Lunch Day.
Internally, Diplomat is sponsoring its own Challenge within a Challenge competition, in which teams of eight will compete for prizes, a smoke-free policy on the company’s campus, weight loss programs and diabetes education programs.
"The health of our patients is incredibly important, and so is the health of the people at Diplomat who take care of them," Diplomat wellness coordinator Becky Foerster said.
FDA panel gives favorable vote to GSK, Theravance COPD drug
LONDON — A Food and Drug Administration panel has recommended that the agency approve an experimental drug for chronic obstructive pulmonary disease made by GlaxoSmithKline and Theravance, the two companies said.
The FDA Pulmonary-Allergy Drugs Advisory Committee voted 9-4 to recommend Breo Ellipta as a long-term maintenance treatment for airflow obstruction in patients with COPD and for reduction of COPD exacerbations in patients with a history of them. The drug is a once-daily inhaler that combines fluticasone furoate and vilanterol.
The panel also voted that the safety of the drug had been adequately demonstrated.
An FDA advisory committee vote does not guarantee approval of a drug, and the agency is not required to follow its recommendation, but usually does.